Low tristetraprolin expression activates phenotypic plasticity and primes transition to lethal prostate cancer in mice.
Phenotypic plasticity is a hallmark of cancer and increasingly realized as a mechanism of resistance to androgen receptor (AR)-targeted therapy. Now that many prostate cancer (PCa) patients are treated upfront with AR-targeted agents, it's critical to …